FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth ...
This health news roundup covers various topics including Gerresheimer's stock jump due to an activist investor, a US list of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback